The carcinogenic chemicals released by degraded Philips CPAP foam are linked to cancers of the nasopharynx, throat, lungs, kidneys, liver, bladder, and thyroid. Nasopharyngeal cancer is the most prevalent diagnosis among MDL 3014 plaintiffs due to direct foam exposure through the breathing pathway.

CPAP cancer claimants can pursue compensation for medical expenses, pain and suffering, lost wages and earning capacity, disability, and wrongful death damages. Projected individual amounts range from $20,000 for non-cancer injury to over $3 million for wrongful death — final amounts depend on the global MDL settlement structure.

The Philips DreamStation — including DreamStation CPAP, Auto CPAP, BiPAP, DreamStation Go, and DreamStation ASV — is the most common recalled device among plaintiffs in MDL 3014. DreamStation users who developed cancer after using the device have among the strongest factual profiles for a CPAP cancer claim.

The strongest CPAP cancer claims have three evidence pillars: proof of device use (receipts, CPAP prescriptions, insurance records), cancer diagnosis documentation (pathology reports, oncology records), and exposure documentation (device model/serial number, ozone cleaner records, use duration). Missing some of these is common — an attorney can help you obtain records.

Most states have 2-year statutes of limitations for CPAP cancer lawsuits. The discovery rule starts the clock when you knew your cancer was linked to your device — but windows are narrowing. Contact an attorney immediately to protect your right to sue.

MDL 3014 (In re: Philips Recalled CPAP Litigation) has over 100,000 personal injury cases pending before Chief Judge Joy Flowers Conti in Pittsburgh. Bellwether trials are targeting a 2026 schedule. Philips has reserved $1.1 billion but no global settlement has been announced. General causation Daubert battles are the current critical battleground.

Nasopharyngeal cancer (NPC) is the most prevalent cancer diagnosis among plaintiffs in MDL 3014. The nasopharynx receives direct chemical exposure from PE-PUR foam degradation byproducts during CPAP use — the clearest anatomical link between device use and cancer development. If you were diagnosed with NPC after using a recalled Philips CPAP, you have one of the strongest potential claims in the MDL.

The polyester-based polyurethane (PE-PUR) foam used as a sound abatement material inside Philips CPAP devices degrades under heat, humidity, and ozone exposure, releasing over 200 chemical compounds — including known and suspected human carcinogens — directly into the breathing pathway. This is the central mechanism of the Philips CPAP cancer litigation.

Philips issued a Class I recall of 15 million CPAP and BiPAP devices in June 2021 after PE-PUR foam was found to release cancer-causing chemicals when it degrades. If you used a recalled device, you may have a legal claim even if you haven't been diagnosed with cancer.

The Philips recall covers CPAP, BiPAP, and ventilator devices manufactured between approximately 2009 and 2021. The DreamStation is the most common plaintiff device. If you used any Philips Respironics device with PE-PUR foam insulation before June 2021, it is very likely recalled.

No global settlement has been announced in MDL 3014 as of early 2026. Attorney projections based on comparable MDL outcomes range from $20,000 for documented non-cancer injuries to $3,000,000+ for wrongful death claims. Your cancer type, stage, device use duration, and documentation quality all affect your case value.